HIV gp41 Peptide Immunogen Stabilization via Conformational Locking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing an effective vaccine against HIV has been hindered by the difficulty in creating an immunogen that elicits broadly neutralizing antibodies, as existing approaches struggle to stabilize the conformation of the gp41 protein and present it in a form that can be recognized by the immune system, particularly due to its membrane-proximal region's occlusion and hydrophobic nature.
Innovation Solution
The development of conformationally stabilized peptide immunogens that bind to the monoclonal antibody 2F5, incorporating disulfide bonds or lactam bridges, and presenting these immunogens in a membrane context using proteoliposomes or virus-like particles to expose the 2F5-bound face while occluding the non-2F5-bound face, combined with a prime-boost strategy to enhance antibody production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the gp41 protein is used as an immunogen, then it can potentially elicit neutralizing antibodies, but its membrane-proximal region is occluded and hydrophobic, making it difficult for the immune system to recognize
Solution Approach 1:
The patent extracts the membrane-proximal region (MPR) epitope from the full gp41 protein and presents it as a standalone stabilized peptide immunogen. This extraction allows the critical neutralizing epitope to be displayed without the occluding membrane environment, making it accessible to the immune system while retaining its neutralizing function.
Solution Approach 2:
The patent applies conformational stabilization through disulfide bonds or lactam bridges to lock the MPR peptide in its native, antibody-binding conformation. This parameter change (from flexible to rigid) prevents conformational drift and ensures the epitope maintains the correct structure for antibody recognition and neutralization.
2Ease of manufacture
If conventional peptide immunogens are used, then they are easy to manufacture, but they fail to stabilize the conformation and present it in a recognizable form
Solution Approach 1:
The patent creates a composite peptide structure by combining the MPR epitope sequence with conformational constraints (disulfide bonds or lactam bridges). This composite design maintains the simplicity of peptide synthesis while incorporating structural elements that lock the conformation, achieving both ease of manufacture and conformational stability.
3Reliability
If the gp41 conformation is stabilized, then it can be recognized by antibodies, but the non-2F5-bound face remains exposed and may not be immunogenic
Solution Approach 1:
The patent applies local quality by differentiating the presentation of the two faces of the MPR peptide. The 2F5-bound face is stabilized and exposed for antibody recognition, while the non-2F5-bound hydrophobic face is occluded by membrane association. This localized differentiation ensures proper immunogenic presentation without compromising stability.
Data Source
AI summary
This invention relates to novel peptide immunogens that generate an immune response in mammals against HIV gp41, to pharmaceutical compositions that comprise such immunogens, and to methods of treating Immunodeficiency disease, especially HIV infection and AIDS, that employ such pharmaceutical compositions.